Since 2006 BGV raised over €120 million across three funds.
It has achieved 8 successful exits and holds 9 active companies in its portfolio.
BGV is currently investing from BGV III
Since our inception in 2006, we have managed over €120 million across our three funds, BGV I, BGV II and BGV III. Our first two funds BGV I and BGV II, launched in 2006 and 2012 respectively, have yielded major successes including Dezima Pharma and Acerta Pharma which were sold within three years at multi-billion dollar deal valuations. We are now actively looking for new seed and early stage investment opportunities in biotech, medtech & diagnostics companies for BGV III launched in 2017.
BGV invests in partnership with other professional investors in life sciences and has built relationships with various leading venture capital investors in the Netherlands, the EU and the US. Ongoing partnerships include Forbion Capital Partners, Ascenion and Mibiton.
Forbion Capital Partners
From its inception, BGV closely collaborates with Forbion Capital Partners. BGV and Forbion are co-located and share the back-office and infrastructure.
BGV is collaborating with Ascenion, the exclusive technology transfer partner to numerous research institutes of the Helmholtz and Leibniz Associations, the Hanover Medical School and associated organizations for translational research.
BGV has a broad investor base: private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors. BGV III is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.